B. Braun Launches Heparin Sodium 2,000 Units in 0.9% Sodium Chloride Injection, 1,000 mL (2 units/mL)
BETHLEHEM, Pa., Feb. 13, 2024 /PRNewswire/ -- B. Braun Medical Inc. (B. Braun), a leader in smart infusion therapy and pain management, announced today the launch of its new Heparin Sodium 2,000 units in 0.9% Sodium Chloride Injection, 1,000 mL (2 units/mL), the fifth product in its portfolio of Heparin premixed bags.
- BETHLEHEM, Pa., Feb. 13, 2024 /PRNewswire/ -- B. Braun Medical Inc. (B. Braun), a leader in smart infusion therapy and pain management, announced today the launch of its new Heparin Sodium 2,000 units in 0.9% Sodium Chloride Injection, 1,000 mL (2 units/mL), the fifth product in its portfolio of Heparin premixed bags.
- This new addition to the portfolio enhances the Company's ability to serve the diverse needs of healthcare facilities and their patients for this high-alert medication.
- The B. Braun Heparin portfolio is manufactured using EXCEL® IV Containers which are not made with natural rubber latex, DEHP or PVC, placing a priority on patient and environmental safety.
- Heparin Sodium 2,000 units in 0.9% Sodium Chloride Injection 1,000 mL (2 units/mL), is indicated as an anticoagulant to maintain catheter patency.